Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
01-023 Harvard Business School Case 201-061 Case Software 201-707 Copyright 2000 by the President and Fellows of Harvard College This case was prepared as the basis for class discussion rather than to illustrate either effective or ineffective handling of an administrative situation.
Exhibit 1
Sales Costs, Expenses, and Other Materials and production Marketing and administrative Research and development Acquired research Equity income from affiliates Gains on sales of businesses Other (income) expense, net Income Before Taxes Taxes on Income Net Income Basic Earnings per Common Share Earnings per Common Share Assuming Dilution Retained Earnings Balance, January 1 Net Income Common Stock Dividends Declared
1997 23,636.9 11,790.3 4,299.2 1,683.7 0 (727.9) (213.4) 342.7 17,174.6 6,462.3 1,848.2 4,614.1 1.92 1.87 14,772.2 4,614.1 (2,094.8) 17,291.5
Exhibit 2
Assets Current Assets Cash and cash equivalents Short-term investments Accounts receivable Inventories Prepaid expenses and taxes Total current assets Investments Property, Plant and Equipment (at cost) Land & Buildings Machinery, equipment and office furnishings Construction in progress Less allowance for depreciation Goodwill and Other Intangibles Other Assets Liabilities and Stockholders Equity Current Liabilities Accounts payable and accrued liabilities Loans payable and current portion of long-term debt Income tax payable Dividends payable Total current liabilities Long-Term Debt Deferred Income Taxes and Noncurrent Liabilities Minority Interests Stockholders Equity Common Stock Other Paid-in capital Retained earnings Accumulated Other Comprehensive Income (loss) Less treasury stock, at cost Total stockholders equity 29.7 5,920.5 23,447.9 8.1 29,406.2 16,164.6 13,241.6 35,634.9 29.7 5,614.5 20,186.7 (21.3) 25,809.6 13,007.8 12,801.8 31,853.4 4,158.7 2,859.0 1,064.1 677.0 8,758.8 3,143.9 7,030.1 3,460.5 3,682.1 624.2 1,125.1 637.4 6,068.8 3,220.8 6,057.0 3,705.0 4,725.0 7,385.7 2,236.3 14,347.0 4,670.3 9,676.7 7,584.2 2,353.3 35,634.9 3,892.8 6,211.7 1,782.1 11,886.6 4,042.8 7,843.8 8,287.2 1,886.2 31,853.4 2,021.9 1,180.5 4,089.0 2,846.9 1,120.9 11,259.2 4,761.5 2,606.2 749.5 3,374.1 2,623.9 874.8 10,228.5 3,607.7
Exhibit 3
Preclinical Testing
Laboratory and animal testing
Phase I
20-80 healthy volunteers used to determine safety and dosage
Phase II
100-300 patient volunteers used t o look for efficacy and side effects
Phase III
1,000-5,000 patient volunteers used to monitor adverse reactions to long-term use.
0
Years
10
12
14
16